Dr. Linda L. Ferris

Hematology
10350 Haligus Rd Ste 120, 
Huntley, IL 
Offers Telehealth
10350 Haligus Rd Ste 120, 
Huntley, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Linda Ferris is a Hematologist in Huntley, Illinois. Dr. Ferris is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in IL
Hospital Affiliations
Northwestern Medicine Mchenry
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

10350 Haligus Rd Ste 120, Huntley, IL 60142

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

1 Total Publications

Treatment Summaries and Survivorship Care Plans: The Approach by the Commission on Cancer to Increase Use.
Treatment Summaries and Survivorship Care Plans: The Approach by the Commission on Cancer to Increase Use.
Journal: Journal of oncology practice
Published: November 27, 2014
Similar Doctors
Advanced in Hemochromatosis
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Leela Bhupalam
Hematology Oncology | Hematology | Oncology

Loyola University Medical Center

2160 S 1st Ave, 
Maywood, IL 
 (38.1 miles away)
708-216-8372
Languages Spoken:
English, Hindi, Kannada
See accepted insurances
Accepting New Patients

Leela Bhupalam is a Hematologist Oncology specialist and a Hematologist in Maywood, Illinois. Dr. Bhupalam is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Angiosarcoma, and Bone Marrow Aspiration. Dr. Bhupalam is currently accepting new patients.

Advanced in Hemochromatosis
Dr. Victor R. Gordeuk
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Victor R. Gordeuk
Hematology Oncology | Hematology | Oncology
820 S Wood St, Sickle Cell Ctr. Suite 172, Clinical Sciences Building, 
Chicago, IL 
 (44.9 miles away)
312-996-5680
Languages Spoken:
English
See accepted insurances

Victor Gordeuk is a Hematologist Oncology specialist and a Hematologist in Chicago, Illinois. Dr. Gordeuk is rated as an Elite provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Bone Marrow Transplant.

Advanced in Hemochromatosis
Dr. Amaryllis Gil
Hematology Oncology | Palliative Medicine | Hematology
Advanced in Hemochromatosis
Dr. Amaryllis Gil
Hematology Oncology | Palliative Medicine | Hematology

Endeavor Health Medical Group

177 E Brush Hill Rd, 
Elmhurst, IL 
 (33.8 miles away)
630-646-6020
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Amaryllis Gil is a Hematologist Oncology specialist and a Palliative Medicine provider in Elmhurst, Illinois. Dr. Gil is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Paget Disease of the Breast, and Breast Cancer. Dr. Gil is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferris's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 96 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile